Advances in the Management of Metastatic Her 2 Positive Breast Cancer
|
|
- Morgan Henry
- 6 years ago
- Views:
Transcription
1 Advances in the Management of Metastatic Her 2 Positive Breast Cancer Sunil Verma MD, MSEd, FRCPC Medical Oncologist Research Lead, Division of Medical Oncology Chair, Breast Medical Oncology Sunnybrook Odette Cancer Centre Associate Professor, University of Toronto
2 The Her 2 Journey HER2 gene is cloned 2 HER2 protein found to be overexpressed in breast tumours 3 Anti-HER2 monoclonal mouse antibody developed 5 Trastuzumab clinical trials begin HER2/neu gene identified 1 HER2 overexpression associated with more aggressive phenotype 4 Anti-HER2 monoclonal mouse antibody humanised: trastuzumab 6 1. Ullrich A, et al. Nature 1984; 309: ; 2. Ishii S, et al. Proc Natl Acad Sci USA 1985; 82: Sainsbury JR, et al. Lancet 1985; 1: ; 4. Di Fiore PP, et al. Science 1987; 237: Huzdiak RM, et al. Mol Cell Biol 1989; 9: ; 6. Carter P, et al. Proc Natl Acad Sci USA 1992; 89:
3 Her 2 Story Poor Prognostic Marker
4 Outline First Line Treatment Second Line Treatment and Beyond Individualized Approach An Algorithm and Concluding Remarks
5 Outline First Line Treatment Second Line Treatment and Beyond Individualized Approach An Algorithm and Concluding Remarks
6 Overall survival (%) Trastuzumab prolongs overall survival in HER2-positive MBC Chemotherapy (n = 234) Chemotherapy + trastuzumab (n = 235) RR = 0.80 (95% CI = 0.64,1.00) p = Median OS: 20.3 months Median OS: 25.1 months Time (months after enrolment) OS was a secondary endpoint in the study Chemotherapy = either doxorubicin or epirubicin + cyclophosphamide or paclitaxel OS, overall survival; RR, relative risk of death Adapted from Slamon DJ, et al. N Engl J Med 2001; 344:
7 First Line Treatment Approach ( ) A number of effective options with chemo and anti-her2 Taxanes and Herceptin Vinorelbine and Herceptin Capecitabine and Anti-Her2 Doublet chemo with Her 2 generally not used Select group of patients may benefit from an anti-her2 and anti-estrogen approach
8 Recent Achievements in Her 2 positive MBC First Line MA.31 Taxane + H vs. Taxane + L Bolero -1 Paclitaxel + H vs. Paclitaxel + H +Everolimus CLEOPATRA Chemo + H vs. Chemo +H+P 8
9 Gelmon et. al ASCO
10 Gelmon et. al ASCO
11 San Antonio Breast Cancer Symposium December 9-13, 2014 BOLERO-1/TRIO 019: Study Design N = 719 Locally advanced or metastatic HER2+ breast cancer No prior therapy for advanced or metastatic disease (except endocrine therapy) Prior (neo)adjuvant TRAS and/or chemotherapy allowed 1 Measurable disease or presence of bone lesions (lytic or mixed) Endpoints Randomized 2:1 Stratification factors: Prior neo/adjuvant TRAS Visceral metastases Everolimus (10 mg PO daily) + Paclitaxel 2 + Trastuzumab 3 Placebo + Paclitaxel 2 + Trastuzumab 3 Therapy until disease progression or intolerable toxicity 4 Primary: PFS (investigator-assessed) Overall population and HR subpopulation Secondary: OS, ORR, CBR, Time to response, Safety, Duration of response 1 Discontinued > 12 mo before randomization; 2 Paclitaxel: 80 mg/m 2 weekly; 3 Trastuzumab: 4 mg/kg loading dose on day 1 at cycle 1 followed by 2 mg/kg weekly doses 4 Patients could discontinue any study treatment due to AEs; other study treatments continued until disease progression or intolerable toxicity ABC, advanced breast cancer; CBR, clnical benefit rate; ORR, overall response rate; OS, overall survival; PFS, progression free survival. This presentation is the intellectual property of the author/presenter. Contact them at shurvitz@mednet.ucla.edu for permission to reprint and/or distribute. 11
12 Probability (%) San Antonio Breast Cancer Symposium December 9-13, 2014 BOLERO-1/TRIO 019: PFS Full Population (Investigator-assessment) 100% 80% Hazard Ratio = 0.89; 95% CI [0.73, 1.08] Log rank p value = Median PFS Everolimus: months; 95% CI [14.55, 17.91] (n/n = 271/480) Placebo: months; 95% CI [12.29, 17.08] (n/n = 154/239) 60% Censoring times 40% 20% 0% Time (months) No. of patients still at risk Everolimus Placebo One-sided p-value is obtained from the log-rank test stratified by prior use of trastuzumab (Y/N) and Visceral metastasis (Y/N) from IWRS. This presentation is the intellectual property of the author/presenter. Contact them at shurvitz@mednet.ucla.edu for permission to reprint and/or distribute. 12
13 San Antonio Breast Cancer Symposium December 9-13, 2014 BOLERO-1/TRIO 019: Most Frequent Adverse Events (Safety set) [> 25% in everolimus arm] AE/Grade EVE + TRAS + PAC (N = 472) % PBO + TRAS + PAC (N = 238) % Any Grade 3 Grade 4 Any Grade 3 Grade 4 Non-hematologic Stomatitis Diarrhea Alopecia 47 < Rash <1 0 Cough 40 < Pyrexia Fatigue Epistaxis Peripheral edema <1 0 Nausea Peripheral neuropathy Headache Vomiting Pneumonitis* <1 0 Hematologic Neutropenia Anemia *AE of clinical importance EVE, Everolimus; HR, hormone receptor; PAC, Paclitaxel; PBO, Placebo; TRAS, Trastuzumab. This presentation is the intellectual property of the author/presenter. Contact them at shurvitz@mednet.ucla.edu for permission to reprint and/or distribute. 13
14 CLEOPATRA study design n=406 Placebo + trastuzumab PD Patients with HER2-positive MBC centrally confirmed (N=808) 1:1 Docetaxel 6 cycles recommended Pertuzumab + trastuzumab PD n=402 Docetaxel 6 cycles recommended Randomization was stratified by geographic region and prior treatment status (neo/adjuvant chemotherapy received or not) HER2, human epidermal growth factor receptor 2; MBC, metastatic breast cancer; PD, progressive disease Swain et al. SABCS 2012 Poster P
15 Progression-free survival (%) Updated Kaplan-Meier curves of investigator-assessed PFS n at risk Ptz + T + D Pla + T + D Ptz + T + D: median 18.7 months Pla + T + D: median 12.4 months Time (months) =6.3 months HR= % CI D, docetaxel; PFS, progression-free survival; Pla, placebo; Ptz, pertuzumab; T, trastuzumab Swain et al. SABCS 2012 Poster P
16 Efficacy Analysis Milestones PFS primary analysis Δ 6.1 months HR 0.62 (p < ) Patients still on placebo offered crossover to pertuzumab May 2011 May 2012 July 2012 Feb 2014 OS 1 st interim analysis OS 2 nd interim analysis OS final analysis HR 0.64 (p = 0.005) HR 0.66 (p = )* 16
17 OS (%) Final OS Analysis Median follow-up 50 months (range 0 70 months) n at risk Ptz + T + D Pla + T + D HR % CI = 0.56, 0.84 p = Time (months) months Δ 15.7 months Ptz + T + D Pla + T + D 56.5 months ITT population. Stratified by geographic region and neo/adjuvant chemotherapy. CI, confidence interval; Pla, placebo; Ptz, pertuzumab. 17
18 Cleopatra Overall Survival Cross over patients (11%) excluded Swain et. al NEJM 2015
19 Breast cancer therapies following discontinuation of study treatment in patients who had withdrawn from study treatment n (%) Placebo + trastuzumab + docetaxel (n=338) Pertuzumab + trastuzumab + docetaxel (n=298) Any 260 (76.9) 225 (75.5) In patients receiving subsequent breast cancer treatment n=260 n=225 Any HER2-targeted treatment 178 (68.5) 160 (71.1) Trastuzumab 104 (40.0) 106 (47.1) Lapatinib 114 (43.8) 93 (41.3) Trastuzumab emtansine 26 (10.0) 21 (9.3) Capecitabine 140 (53.8) 113 (50.2) Vinorelbine 70 (26.9) 51 (22.7) Cyclophosphamide 43 (16.5) 30 (13.3) Doxorubicin 46 (17.7) 29 (12.9) Paclitaxel 32 (12.3) 21 (9.3) Docetaxel 11 (4.2) 13 (5.8) Swain et al. SABCS 2012 Poster P
20 Adverse events (all grades) with 25% incidence or 5% difference between arms n (%) Placebo + trastuzumab + docetaxel (n=396) Pertuzumab + trastuzumab + docetaxel (n=408) Diarrhea 191 (48.2) 278 (68.1) Alopecia 240 (60.6) 248 (60.8) Neutropenia 197 (49.7) 216 (52.9) Nausea 168 (42.4) 179 (43.9) Fatigue 148 (37.4) 155 (38.0) Rash 95 (24.0) 149 (36.5) Decreased appetite 105 (26.5) 121 (29.7) Mucosal inflammation 79 (19.9) 112 (27.5) Asthenia 121 (30.6) 110 (27.0) Vomiting 97 (24.5) 104 (25.5) Peripheral edema 122 (30.8) 101 (24.8) Pruritus 40 (10.1) 68 (16.7) Constipation 101 (25.5) 63 (15.4) Febrile neutropenia 30 (7.6) 56 (13.7) Dry skin 23 (5.8) 44 (10.8) Highlighted are adverse events with 5% higher incidence Swain et al. SABCS 2012 Poster P
21 Cardiac adverse events n (%) Data cutoff date May 2011 (n=397) Placebo + trastuzumab + docetaxel May 2012 (n=396) Pertuzumab + trastuzumab + docetaxel May 2011 (n=407) May 2012 (n=408) LVSD (all grades) 33 (8.3) 34 (8.6) 18 (4.4) 22 (5.4) Symptomatic LVSD 7 (1.8) 7 (1.8) 4 (1.0) 5 (1.2) LVEF decline to <50% and by 10% points from baseline* 25/379 (6.6) 28/378 (7.4) 15/393 (3.8) 18/394 (4.6) LVEF recovery to 50%* 18/25 (72.0) 25/28 (89.3) 13/15 (86.7) 16/18 (88.9) * In patients with post-baseline assessment LVEF, left ventricular ejection fraction; LVSD, left ventricular systolic dysfunction Swain et al. SABCS 2012 Poster P
22 T-DM1 Mechanism of Action KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate consisting of HERCEPTIN, a humanized anti-her2 IgG1 monoclonal antibody DM1, a cytotoxic microtubule inhibitor derived from maytansine on average, KADCYLA has 3.5 DM1 molecules per antibody MCC, a stable thioether linker, covalently linking HERCEPTIN to DM1 Antibody (HERCEPTIN) Stable linker Cytotoxic agent (DM1) Emtansine DM: derivative of maytansine MCC: 4-[N-maleimidomethyl] cyclohexane-1- carboxylate KADCYLA Product Monograph. Hoffmann-La Roche Limited. September 11, Swanton C, Johnston SR, editors. Handbook of Metastatic Breast Cancer, 2 nd ed. Informa Healthcare, New York, 2012.
23 T-DM1 Retains Activity of Herceptinf In vitro studies in human breast cancer cells that overexpress HER2 have shown that, like HERCEPTIN, KADCYLA Binds subdomain IV of the HER2 extracellular domain Inhibits HER2 signaling Mediates antibody-dependent cell-mediated cytotoxicity (ADCC) Inhibits shedding of the HER2 extracellular domain KADCYLA Product Monograph. Hoffmann-La Roche Limited. September 11, 2013.
24 T-DM1 Intracellular Delivery of DM1 HER2 KADCYLA DM1 release* Internalization Lysosomal degradation Inhibition of tubulin polymerizatio n KADCYLA has the additional MOA of DM1. Upon binding to HER2, KADCYLA undergoes Receptor-mediated internalization Subsequent lysosomal degradation Intracellular release of DM1-containing cytotoxic catabolites DM1 binding to tubulin, disrupting microtubule networks in the cell, resulting in cell cycle arrest and apoptotic cell death *The primary DM1-containing cytotoxic catabolite released is lysine-mcc-dm1. KADCYLA Product Monograph. Hoffmann-La Roche Limited. September 11, LoRousso PM, et al. Clin Cancer Res 2011.
25 PHASE II STUDY T-DM1 vs. Docetaxel and Trastuzumab 1:1 HER2-positive, recurrent locally advanced breast cancer or MBC (N=137) Trastuzumab 8 mg/kg loading dose; 6 mg/kg q3w IV + Docetaxel 75 or 100 mg/m 2 q3w (n=70) T-DM1 3.6 mg/kg q3w IV (n=67) PD a PD a Crossover to T-DM1 (optional)
26 Objective Response by Investigator Patients With Measurable Disease at Baseline Trastuzumab + docetaxel (n=69) a T-DM1 (n=67) Patients with an objective response, b n (%) 40 (58.0) 43 (64.2) 95% CI Objective responses, n (%) Complete response 3 (4.3) 7 (10.4) Partial response 37 (53.6) 36 (53.7) Stable disease 23 (33.3) 13 (19.4) Progressive disease 4 (5.8) 8 (11.9) Unable to evaluate or missing 2 (2.9) 3 (4.5) Patients with clinical benefit, c n (%) 56 (81.2) 50 (74.6) 95% CI a One patient was not included in the efficacy analysis due to study site withdrawal. b Defined as complete or partial response based on RECIST 1.0 determined on 2 consecutive tumor assessments at least 4 weeks apart. c Defined as objective response any time during the study or maintained stable disease for at least 6 months from randomization. Hurvitz, et al., JCO, 2013 Hurvitz SA, et al. Abstract ESMO 2011.
27 Proportion progression-free Progression-Free Survival by Investigator Randomized Patients 1.0 Median PFS, mos Hazard ratio 95% CI Log-rank P value 0.8 Trastuzumab + docetaxel (n=70) T-DM1 (n=67) Number of patients at risk Time (months) T+D T-DM Hazard ratio and log-rank P value were from stratified analysis. This presentation contains non-licensed product information and may be subject to local affiliate compliance and / or legal approval before onward internal distribution. This information is for internal use only and must not be distributed externally Hurvitz, et al., JCO, 2013
28 MARIANNE: A clinical trial of pertuzumab and T-DM1 in first-line metastatic breast cancer Pertuzumab + T-DM1 HER2-positive, progressive or recurrent, locally advanced or untreated MBC (N = 1092) R Placebo + T-DM1 Trastuzumab + taxane (docetaxel or paclitaxel) T-DM1 ± pertuzumab: blinded, placebo-controlled Trastuzumab + taxane: open-label First patient in July 2010 Last patient in Q Figure adapted from: Roche. Data on file
29 MARIANNE Statistical Analysis
30 Summary First Line The standard of care should consist of pertuzumab and trastuzumab along with docetaxel (? other taxane alternative) 31
31 Future Questions First Line Can we combine Pertuzumab and Herceptin with other partners Other taxanes (PERUSE) Other chemotherapies - Vino/Cape (VELVET/PHREXA) Other biologics T-DM1 (MARIANNE negative) Developing effective drugs that can target brain metastases Duration of targeted therapy for those responding Duration of chemotherapy when receiving dual targeted therapy Combination of endocrine therapy with dual targeted anti-her 2 tx for ER+/Her 2 +ve pts 32
32 Outline First Line Treatment Second Line Treatment and Beyond Individualized Approach An Algorithm and Concluding Remarks
33 Second Line ( ) There is continued benefit of trastuzumab beyond progression Capecitabine and Trastuzumab There is benefit of Lapatinib in combination with Capecitabine upon progression on Trastuzumab
34 Recent Achievements in Her 2 positive MBC Second Line and Beyond EGF L+ H vs L alone EMILIA T-DM1 vs Cape + L Bolero-3 Vinorelbine + H + Everolimus vs. Vinorelbine + H 35
35 Trastuzumab and Lapatinib Overall Survival
36 EMILIA Study Design HER2-positive LABC or MBC (N=980) Prior taxane and trastuzumab Progression on metastatic treatment or within 6 months of adjuvant treatment 1:1 T-DM1 3.6 mg/kg q3w IV Capecitabine 1000 mg/m 2 PO bid, days 1 14, q3w + Lapatinib 1250 mg/day PO qd PD PD Verma et al NEJM 2012
37 EMILIA: Progression Free Survival Verma et al NEJM 2012
38 EMILIA: Overall Survival Verma et al NEJM 2012
39 EMILIA Adverse Events Verma et al NEJM
40 TH3RESA Study Schema HER2-positive (central) advanced BC a (N=600) 2 T-DM1 3.6 mg/kg q3w IV (n=400) PD 2 prior HER2-directed therapies for advanced BC Prior treatment with trastuzumab, lapatinib, and a taxane 1 Treatment of physician s choice (TPC) b (n=200) PD T-DM1 c (optional crossover) Stratification factors: World region, number of prior regimens for advanced BC, d presence of visceral disease Co-primary endpoints: PFS by investigator and OS Key secondary endpoints: ORR by investigator and safety a Advanced BC includes MBC and unresectable locally advanced/recurrent BC. b TPC could have been single-agent chemotherapy, hormonal therapy, or HER2-directed therapy, or a combination of a HER2-directed therapy with a chemotherapy, hormonal therapy, or other HER2-directed therapy. c First patient in: Sep Study amended Sep 2012 (following EMILIA 2nd interim OS results) to allow patients in the TPC arm to receive T-DM1 after documented PD. d Excluding single-agent hormonal therapy. BC, breast cancer; IV, intravenous; ORR, objective response rate; PD, progressive disease; q3w, every 3 weeks. Wildiers H, et al. ECC 2013; Abstract 15LBA.
41 Proportion progression-free PFS by Investigator Assessment TPC (n=198) T-DM1 (n=404) Median (months) No. of events Stratified HR=0.528 (95% CI, 0.422, 0.661) P< Time (months) No. at risk: TPC T-DM Median follow-up: TPC, 6.5 months; T-DM1, 7.2 months. Unstratified HR=0.521 (P<0.0001). Wildiers H, et al. ECC 2013; Abstract 15LBA.
42 Proportion surviving First Interim OS Analysis 1.0 Observed 21% of targeted events No. at risk: TPC 198 T-DM Time (months) TPC (n=198) T-DM1 (n=404) Median (months) 14.9 NE No. of events Stratified HR=0.552 (95% CI, 0.369, 0.826); P= Efficacy stopping boundary HR<0.363 or P< patients in the TPC arm received crossover T-DM1 treatment after documented progression. Unstratified HR=0.57 (P=0.004). Wildiers H, et al. ECC 2013; Abstract 15LBA.
43 O Regan R, et al. ASCO 2013; Abstract 505. Not for distribution. O Regan ASCO
44 O Regan R, et al. ASCO 2013; Abstract 505. Not for distribution. O Regan ASCO
45 Summary Second Line and Beyond T-DM1 offers significant clinical benefit and superior toxicity profile and is effective for second line Her 2 + treatment Patients progressing on T-DM1 still may derive a benefit from ongoing systemic tx with chemo with anti-her 2 approaches The role of Lapatinib has evolved and now is generally considered in third or later lines of treatment. One may consider earlier use if: Progressive brain metastases despite radiation Lack of response to first/second line of herceptin based regimen? Biomarkers p95 still needs to be validated 46
46 Future Questions Is there a benefit of Pertuzumab or T-DM1 (along with other partners) beyond progression? What is the effect on tumor biology once patients progress on Pertuzumab/T-DM1? What are potential targeted agents that may help overcome resistance? What will be the role of PI3K inhibitors in second line + treatment? Who are the ideal patients for dual targeted treatment alone? The Next Generation of anti-her 2 Drugs. 47
47 PHEREXA: A clinical trial of pertuzumab in second-line metastatic breast cancer Arm A: Pertuzumab + trastuzumab + capecitabine HER2-positive MBC (N = 450) R Arm B: Trastuzumab + capecitabine Last patient in Q3 Figure adapted from: Muñoz-Mateu M, et al. ASCO 2011 (Abstract TPS118: poster presentation); Roche. Data on file.
48
49 MM-302 is a HER2-targeted antibody-drug conjugated liposomal formulation anti-her2 scfv Targets liposome to HER2-overexpressing cells Promotes internalization Binds to different epitope than trastuzumab Does not inhibit HER2 signaling No uptake of F5 containing liposomes into cardiomyocytes Liposome Extended half-life Stably encapsulates doxorubicin Passive accumulation in tissues possessing leaky vasculature Size precludes delivery to cardiac tissue Lipid Membrane PEG nm Doxorubicin Crystals Effective cytotoxic agent in Br Ca DNA intercalator, TOP2A inhibitor, free radical generator
50 T cell dependent bispecific antibody (TDB) platform Hole: acd3 Knob: atumor antigen Full length TDB + = T366S L368A Y407V T366W Produced using modular knobs into holes technology Effector functions removed (E. coli production / N297A) Minimal immunogenic potential PK is similar to conventional IgG1 Ridgeway...Carter Prot. Engineering Atwell...Carter J. Mol Biol.
51 Outline First Line Treatment Second Line Treatment and Beyond Individualized Approach An Algorithm and Concluding Remarks
52 Personalized Factors to Consider Hormone Receptor Status Prior Adjuvant Trastuzumab CNS Metastases Biomarkers
53 CLEOPATRA PFS in predefined subgroups Prior (neo)adjuvant chemotherapy Region Age group Race All No Yes Europe North America South America Asia <65 years 65 years <75 years 75 years White Black Asian Other Favors pertuzumab Favors placebo Hormone Receptor Status n HR 95% CI Disease type ER/PgR status HER2 status Visceral disease Non-visceral disease Positive Negative IHC 3+ FISH-positive ER, estrogen receptor; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; PFS, progression-free survival; PgR, progesterone receptor Swain et al. SABCS 2012 Poster P
54 Cleopatra PFS Subgroup Analysis
55 Cleopatra OS Subgroup Analysis
56 EMILIA Overall Survival Subgroup Analyses Cap + Lap T-DM1 Baseline Total Median Median HR characteristic n (mos) (mos) (95% CI) All patients (0.56, 0.87) Age group <65 years (0.52, 0.83) years NR 0.74 (0.37, 1.47) 75 years 25 NR (0.94, 12.65) ER and PR status ER+ and/or PR (0.46, 0.85) ER and PR (0.54, 1.03) Line of therapy a First-line NR 0.61 (0.32, 1.16) Second-line 361 NR (0.61, 1.27) Third- and later-line (0.46, 0.84) T-DM1 Better Cap + Lap Better Hazard ratio a Defined as any systemic therapy including endocrine and chemotherapy. NR, not reached. From confirmatory OS analysis; data cut-off July 31, Verma et al. ESMO 2012; Oral Abstract #LBA12 Hormone Receptor Status
57 Hormone Receptor Status BOLERO-3: PFS Subgroup Analyses by Local Assessment Subgroup N All 569 Age < 65 years Region Europe 223 North America 123 Asia 166 Latin America 36 Other 21 Prior lapatinib* Yes 161 No 408 Prior adj/neo trastuzumab** Yes 251 No 318 Baseline ECOG PS or Hormonal status ER /PgR 250 ER + /PgR Visceral involvement Yes 439 No 130 Hazard Ratio [95% CI] 0.78 [ ] 0.77 [ ] 0.93 [ ] 0.72 [ ] 0.86 [ ] 0.83 [ ] 0.61 [ ] 1.28 [ ] 0.79 [ ] 0.78 [ ] 0.65 [ ] 0.92 [ ] 0.79 [ ] 0.75 [ ] 0.65 [ ] 0.93 [ ] 0.89 [ ] 0.48 [ ] Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status. Favors EVE Favors PBO 58 O Regan R, et al. ASCO 2013; Abstract 505. Not for distribution.
58 Probability (%) San Antonio Breast Cancer Symposium December 9-13, 2014 BOLERO-1/TRIO 019: PFS HR Subpopulation (Investigator Assessment) 100% Hazard Ratio = 0.66; 95% CI [0.48, 0.91] Log rank p value = % 60% Median PFS Everolimus: months; 95% CI [14.95,24.08] (n/n = 97/208) Placebo: months; 95% CI [10.05,16.56] (n/n = 66/103) Censoring times 40% 20% 0% Time (months) No. of patients still at risk Everolimus Placebo One-sided p-value is obtained from the log-rank test stratified by prior use of trastuzumab (Y/N) and Visceral metastasis (Y/N) from IWRS. Sensitivity analysis without censoring patients at the start of new antineoplastic therapy: Median PFS and 95% CIs HR=0.66 [0.48, 0.9], p = mo (14.82, 24.08) for everolimus [n = 102] mo (10.94, 16.56) for placebo [n = 68] This presentation is the intellectual property of the author/presenter. Contact them at shurvitz@mednet.ucla.edu for permission to reprint and/or distribute. 59
59 Prior Trastuzumab CLEOPATRA: Independently assessed PFS by prior trastuzumab therapy in patients with (neo)adjuvant therapy HT Median PFS, months PHT Median PFS, months Hazard ratio (CI) Prior (neo)adjuvant trastuzumab treatment (n = 88) (0.35, 1.07) No prior (neo)adjuvant trastuzumab treatment (n = 288) (0.43, 0.83) CI, confidence interval; PFS, progression-free survival Adapted from Baselga J, et al. N Engl J Med 2012; 366:
60 Cleopatra OS Subgroup Analysis
61 EMILIA: Progression-Free Survival Subgroup Analyses Baseline characteristic All pts Total n 991 Cap + Lap Median, mos 6.4 T-DM1 Median, mos HR (95% CI) (0.56, 0.78) Prior Trastuzumab T-DM1 better Cap + Lap better Age <65 yrs 65 yrs (0.52, 0.74) 1.06 (0.68, 1.66) ER and PR status ER+ and/or PR+ ER and PR (0.58, 0.91) 0.56 (0.44, 0.72) Line of therapy a First Second Third (0.30, 0.85) 0.69 (0.53, 0.91) 0.69 (0.55, 0.86) Data cut-off Jan 14, 2012 HRs were from unstratified analysis. a Defined as any systemic therapy, including endocrine or chemotherapy. Hazard ratio Verma et al. N Eng J Med 2012 (incl. supplementary appendix) Blackwell et al. ASCO 2012; Abst #LBA1
62 Prior Trastuzumab EMILIA: Overall Survival Subgroup Analyses Cap + Lap T-DM1 Baseline Total Median Median HR characteristic n (mos) (mos) (95% CI) All patients (0.56, 0.87) T-DM1 Better Cap + Lap Better Age group <65 years (0.52, 0.83) years NR 0.74 (0.37, 1.47) 75 years 25 NR (0.94, 12.65) ER and PR status ER+ and/or PR (0.46, 0.85) ER and PR (0.54, 1.03) Line of therapy a First-line NR 0.61 (0.32, 1.16) Second-line 361 NR (0.61, 1.27) Third- and later-line (0.46, 0.84) Hazard ratio a Defined as any systemic therapy including endocrine and chemotherapy. NR, not reached. From confirmatory OS analysis; data cut-off July 31, Verma et al. ESMO 2012; Oral Abstract #LBA12
63 CNS Metastases EMILIA CNS metastases at baseline and Progression 64
64 EMILIA: Outcomes of patients with CNS mets at Baseline A. PFS Independent Assessment B. PFS Investigator Assessment D. Overall Survival Krop et. al Annals of Oncology
65 66
66 BIOMARKERS 67
67 Alterations in PI3K Pathway Signaling Components Are Frequent in HER2+ Breast Cancer 20% 10% 68 BGT226A2101 CONFIDENTIAL INFORMATION, NOT TO BE DISTRIBUTED
68 PI3K Pathway activation status Predicts Response to Trastuzumab Bernard R et al Cancer Cell Oct;12(4):
69 pcr and PIK3CA Status by Treatment Arm in NEO-ALTTO For each treatment arm, the pcr rate was lower in tumors with a PIK3CA mutation The difference was statistically significant in the combination arm p=0.012 N= Baselga AACR
70 PIK3CA Mutation Associated With Poorer Prognosis on Both Arms of Cleopatra Study Baselga et al, SABCS 2012
71 Proportion progression-free EMILIA Biomarker Analysis: PFS by PIK3CA Mutation Status and Treatment Arm PIK3CA mutation status Lap + Cap n Median (months) n T-DM1 Median (months) Hazard ratio a 95% CI Mutated Wild type No. at risk: Lap + Cap (PIK3CA mutated) Lap + Cap (PIK3CA wild type) T-DM1 (PIK3CA mutated) T-DM1 (PIK3CA wild type) Time (months) Lap + Cap (Mutated) Lap + Cap (Wild type) T-DM1 (Mutated) T-DM1 (Wild type) a Hazard ratios are based on unstratified analyses. Baselga et al, SABCS 2013
72 Proportion surviving EMILIA Biomarker Analysis: OS by PIK3CA Mutation Status and Treatment Arm Lap + Cap T-DM1 PIK3CA mutation status n Median (months) n Median (months) Hazard ratio a 95% CI Mutated NE Wild type NE No. at risk: Lap + Cap (Mutated) Lap + Cap (Wild type) T-DM1 (Mutated) T-DM1 (Wild type) a Hazard ratios are based on unstratified analyses NE, not estimable. Lap + Cap (PIK3CA mutated) Lap + Cap (PIK3CA wild type) T-DM1 (PIK3CA mutated) T-DM1 (PIK3CA wild type) Time (months)
73 Outline First Line Treatment Second Line Treatment and Beyond Individualized Approach An Algorithm and Concluding Remarks
74 HISTORY 30 YEARS IN THE MAKING
75 Milestones in the Management of HER2-positive MBC Overall Survival First Line Second Line + Abbreviations: Ana, anastrozole; Cape, capecitabine; CT, chemotherapy; Doc, docetaxel; Lap, lapatinib; Let, letrozole; OS, overall survival; Pac, paclitaxel; Pert, pertuzumab; T-DM1, trastuzumab emtansine; Tras, trastuzumab. Verma et. al The Oncologist 2013
76 An Algorithm to Manage Her 2 positive MBC Verma et. al The Oncologist 2013
77 An Algorithm to Manage Her 2 positive MBC Can we consider Pertuzumab for DFI 6m- 1year? Can we consider another taxane with P + H? Is there still activity of Trastuzumab/Lapatini b post T-DM1? Verma et. al The Oncologist 2013
78 Beyond Breast Cancer Development of Targeted Therapy
79 Conclusion Raising the Bar The outcome of patients with Her 2 positive breast cancer has significantly improved in the past two decades Novel targeted drugs are improving survival and reducing toxicity for patients with advanced breast cancer The future looks quite bright as we can now envision a total targeted approach for some of these patients..and an overall survival in excess of five years for some of our patients!
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationTarge:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationAdvanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationPROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
More informationNew Drug Development in HER2+ Breast Cancer
New Drug Development in HER2+ Breast Cancer Philippe Aftimos, M.D. Senior Research Physician Clinical Pharmacology Unit Institut Jules Bordet Background Amplification of HER2 occurs in approximately 20%
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationLo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento
Lo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento TRASTUZUMAB most important breakthrough in the management of BC Trastuzumab
More informationBreast cancer update. Iryna Kuchuk, MD Oncology department Meir Medical Center
Breast cancer update Iryna Kuchuk, MD Oncology department Meir Medical Center Overview Cancer Death Rates* Among Women, US,1930-2009 Factors Associated with Reduction In Breast Cancer Mortality Early
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationEmerging Agents in HER2-positive Disease. Mary Cianfrocca, DO Director, Breast Oncology Program Banner MD Anderson Cancer Center Gilbert, AZ
Emerging Agents in HER2-positive Disease Mary Cianfrocca, DO Director, Breast Oncology Program Banner MD Anderson Cancer Center Gilbert, AZ Signal Transduction by the HER Family and Potential Mechanisms
More informationDisease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
More informationUpdate in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
More informationHER2 Biology and Treatment in Breast Cancer
HER2 Biology and Treatment in Breast Cancer Sandra M. Swain, MD, FACP Director, Washington Cancer Institute Washington Hospital Center Professor of Medicine Georgetown University Washington DC Off-Label
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationNuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento
Nuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento Prof. Sabino De Placido Dip. di Endocrinologia ed Oncologia
More information2014 San Antonio Breast Cancer Symposium Review
2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More informationJosé Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
More informationKarcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski
Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,
More informationHer 2 Positive Metastatic Breast Cancer
Her 2 Positive Metastatic Breast Cancer Alison Jones November 2013 Mrs Hermione Positive (then and now!) Diagnosed 2007 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2010metastatic
More informationInnovations In The Management Of
Innovations In The Management Of HER2+ Breast Cancer Dr. Sandeep Goyle Consultant Medical Oncologist Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute Mumbai, India Introduction - Self
More informationEnfermedad con sobreexpresión de HER-2 neu
Enfermedad con sobreexpresión de HER-2 neu Elsa Dalmau Parc Taulí Sabadell. Hospital Universitari. Enfermedad con sobreexpresión de HER-2 neu ÍNDICE Neoadyuvancia Adyuvancia Enfermedad avanzada Enfermedad
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Management of HER2+ MBC SOBO 2012 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for Women s Cancer
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationRIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationMEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014
MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014 Dr Thomas Yau Clinical Assistant Professor MBBS(HK), MRCP (UK), FHKCP (Med Onc), FHKAM( Medicine), FRCP(London) Queen Mary Hospital The University of Hong Kong
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationCáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
More informationPIK3CA Mutations in HER2-Positive Breast Cancer
2016.4.29. GBCC PIK3CA Mutations in HER2-Positive Breast Cancer Seock-Ah Im, MD, PhD. Department of Internal Medicine Seoul National University Hospital Contents Introduction TCGA data HER2 signaling pathway
More informationPositive HER-2 tumor. How to incorporate the new drugs into neoadjuvance
Oncology Department Vall d Hebron University Hospital Barcelona. Spain Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance Javier Cortés June/2013 MD Anderson experience Buzdar et
More informationPresent and emerging treatment options in Her-2/neu overexpressing metastatic breast cancer
Present and emerging treatment options in Her-2/neu overexpressing metastatic breast cancer Christoph C. Zielinski Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center,
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More informationSystemic therapy for HER2+ Advanced Breast Cancer
Systemic therapy for HER2+ Advanced Breast Cancer F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESMO Board of Directors & NR Committee Chair ESO Breast Cancer Program
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach
More informationSustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA
Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More informationPost-ESMO 2012: Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich T.Rordorf, SAMO Luzern 1
Post-ESMO 2012: Breast Cancer Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich 1 Neoadjuvant treatment (in Her-2 positive disease) neoadjuvant trials abstracts: breast sparing surgery, biomarkers,
More informationEndocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationFDA Briefing Document Oncologic Drugs Advisory Committee Meeting. September 12, sbla /51 Pertuzumab (PERJETA ) Applicant: Genentech, Inc.
/51 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting September 12, 2013 /51 Pertuzumab (PERJETA ) Applicant: Genentech, Inc. Disclaimer: The attached package contains background information
More informationPost-ASCO 2017 Cancer du sein Triple Négatif
Post-ASCO 217 Cancer du sein Triple Négatif A.Ladjeroud, K.Bouzid Centre Pierre et Marie Curie- Alger Oran, 3 Septembre 217 Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationChallenges and Success: Treatment of Metastatic Breast Cancer 2012
Challenges and Success: Treatment of Metastatic Breast Cancer 2012 Hope S. Rugo University of California San Francisco Helen Diller Family Comprehensive Cancer Center This presentation is the intellectual
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationPolicy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015
Medication Policy Manual Topic: Perjeta, pertuzumab Committee Approval Date: May 9, 2014 Policy No: dru281 Date of Origin: September 24, 2012 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationMetronomic chemotherapy for breast cancer
Metronomic chemotherapy for breast cancer M. Colleoni International Breast Cancer Study Group (IBCSG), Division of Medical Senology, European Institute of Oncology Metronomic Scheduling and Inhibition
More information非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationTarget biologico e meccanismo d azione dei farmaci anti-her2: il continuum dal setting Neoadiuvante alla malattia metastatica
Target biologico e meccanismo d azione dei farmaci anti-her2: il continuum dal setting Neoadiuvante alla malattia metastatica Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental
More informationDEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO CÁNCER DE MAMA HER 2 POSITIVO
DEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO CÁNCER DE MAMA HER 2 POSITIVO DEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Pertuzumab (Perjeta) for Metastatic Breast Cancer August 1, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Pertuzumab (Perjeta) for Metastatic Breast Cancer August 1, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationMetastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2. - Valentina Sini -
Metastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2 - Valentina Sini - Metastatic Breast Cancer ER- Her2-20% ER- Her2+ ER+ Her2+ 5% 15% ER+ Her2- ER+ Her2+ ER- Her2+
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationIncorporating biologics in the management of older patients with metastatic colorectal cancer
Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT
ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE
More informationThe Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationBreast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
More informationEndocrine treatment might NOT be the preferred option in Hrpos MBC. Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015
Endocrine treatment might NOT be the preferred option in Hrpos MBC Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015 Overall survival not improved by the AI treatment Benefit in
More informationOPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx ANTHRACYCLINES AND TAXANES ARE COMMONLY USED USED IN MOST REGIMENS
More informationCancer du sein métastatique et amélioration de la survie Pr. X. Pivot
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Trastuzumab Emtansine (Kadcyla) for Metastatic Breast Cancer January 10, 2014
pan-canadian Oncology Drug Review Final Clinical Guidance Report Trastuzumab Emtansine (Kadcyla) for Metastatic Breast Cancer January 10, 2014 DISCLAIMER Not a Substitute for Professional Advice This report
More information10/15/2012. Overcoming Endocrine Therapy Resistance. The Problem in ER+ Tumors is Endocrine Therapy Resistance
Overcoming Endocrine Therapy Resistance Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Slide Credits: Hope Rugo, MD The Problem in ER+ Tumors is Endocrine Therapy Resistance
More informationLead team presentation Eribulin for treating locally advanced or metastatic breast cancer after two or more prior chemotherapy regimens STA
For projector and public [noacic] Lead team presentation Eribulin for treating locally advanced or metastatic breast cancer after two or more prior chemotherapy regimens STA 1 st Appraisal Committee meeting
More informationTITLE: Systemic Therapy for Patients with Advanced HER2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
TITLE: Systemic Therapy for Patients with Advanced HER2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Table of Contents Data Supplement 1: Additional Evidence
More informationPage. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck
Hormone Therapy Resistance: Challenges and Opportunities Pamela. N. Munster, MD University of California, San Francisco Financial Disclosures Research Support From Merck Objectives: Understanding the current
More informationExpert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides
Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer Reference Slides Overview BRCA Mutations and Breast Cancer Patients with BRCA mutations have an estimated 55% to 65% cumulative
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationPertuzumab for the adjuvant treatment of HER2-positive breast cancer
Lead team presentation Pertuzumab for the adjuvant treatment of HER2-positive breast cancer 1 st Appraisal Committee meeting Background and clinical effectiveness Committee A Lead team: John McMurray,
More informationTargeted Therapies in Melanoma
Mutations and Targets Targeted Therapies in Melanoma ckit NRAS
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationBreast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
More informationTreatment of Early-Stage HER2+ Breast Cancer
Treatment of Early-Stage HER2+ Breast Cancer Chau T. Dang, MD Chief, MSK Westchester Medical Oncology Service Breast Medicine Service Memorial Sloan Kettering Cancer Center Disclosures I have research
More information